Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.
Chapters explore therapeutic RNAs, RNA stability, mRNA vaccine formulation, strategies to overcome immunogenicity, delivery hurdles, mRNA-based cancer immunotherapy, CAR and TCR T cell therapies, and RNA interference.
RNA therapeutics: Bridging discovery and clinical implementation.- Molecular mechanisms of innate immune sensing of exogenous RNAs.- Chemical modifications in nucleic acid therapeutic.- Effects of nucleoside modifications on mRNA Translation: Choosing the right modifications.- Generation of lipid nanoparticle mRNA vaccines and evaluation of antigen specific CD8+ T cell responses.- Assessing the immunogenicity of synthetic RNA using blood cells.- Lateral flow immunoassay for rapid and sensitive detection of dsRNA contaminants in in vitro-transcribed mRNA products.- Hydrophobic chromatography purification of linearized Plasmid DNA reduces dsRNA formation during in vitro transcription.- Optimization of In vitro transcription reaction for mRNA production using chromatographic at-line monitoring.- Large scale production of unmodified mRNA for reprogramming human dendritic cells and T cells.- Production of mRNA-loaded dendritic cell cancer vaccines.- Enhancing cancer vaccine efficacy: siRNA-based modulation of immune suppressive factors in dendritic cells.- mRNA-based engineering of viral antigen-specific TCR-T cells.- Engineering mRNA CAR-T cells for cancer immunotherapy.- Generating mRNA encoding anti-HBV designer epigenome modifiers.- Lipid nanoparticles for the delivery of mRN.- Optimization of DOTAP/cholesterol cationic lipid nanoparticles for nucleic acid delivery.- Formulation and characterization of cationic bicelles for siRNA delivery.- Bioinspired extracellular vesicles for enhanced delivery of siRNA to tumours.- Construction of nanotube-shaped mRNA vehicles using self-assembling peptides.- Nanoparticle-mediated siRNA delivery in human epithelial lung cells cultured at the air-liquid interface.- Developing aptamer-targeted mRNA for immunotherapy.- A facile method for assessing cellular stability and co-localization of Cas9 mRNA and sgRNA using confocal microscopy.- siRMSD: A structural parameter to reduce sequence-dependent off-target effects for siRNA design with chemical modifications.- Chemical strategies to enhance antisense strand selection and minimize off-target effect-mediated by siRNAs.- In vivo fermentation production of RNA interference agents.
